New CSF Biomarkers for Alzheimer's Disease

Recruiting

• Conditions: Neurodegenerative Diseases; Alzheimer Disease; Dementia

• Registration Number: NCT03621839
• Lead Sponsor: Central Hospital, Nancy, France

Brief Summary

Today, the Alzheimer's disease (AD) diagnosis is founded not only on clinical criteria but also on complementary examinations to confirm a physiopathological process of AD. In complex cases, lumbar punction could be necessary in order to measure Aβ peptides and Total and phosphorylated Tau but new biomarkers could be useful. The main objective of this project is to conserve these cerebrospinal fluids, collected in usual practice in order to validate new biomarkers for diagnosis, prognosis or therapeutic following of Alzheimer's disease and other dementia.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-07-12
• Study First Submitted: 2018-07-25
• Study First Submitted QC: 2018-08-03
• Study First Posted: 2018-08-09
• Status Verified: 2023-12
• Last Update Submitted: 2024-03-05
• Last Update Posted: 2024-03-06
• Primary Completion: 2050-12-31
• Study Completion: 2050-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 50000

Inclusion Criteria

• Lumbar punction collected in usual practice in the context of dementia diagnosis

Exclusion Criteria

• Absence of consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
CSF collection constitution to have samples available for assessing new Alzheimer's biomarker	50 years	Each CSF collected in the context of dementia diagnosis were conserved to be used in other studies on Alzheimer's or dementia biomarkers. Futre studies that will use collected CSF to assess new biomarkers will be conduced under a new protocol describing scientific contexte, specific aims and time frame necessary to achieve them.

Trial Locations

Locations (1)

CHRU De Nancy; 🇫🇷 Nancy, Grand Est, France